LOAMS
BCRX icon

Lombard Odier Asset Management (Switzerland)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-317,901
Closed -$2.65M – 170
2023
Q1 		$2.65M Buy
317,901
+182,839
+135% +$1.76M 0.23% 106
2022
Q4 		$1.55M Buy
+135,062
New +$1.68M 0.12% 140

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s BCRX Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 317,901 shares — an estimated $2.65M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in BCRX in Q4 2022 and held it in 2 quarters. The position peaked at $2.65M in Q1 2023. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • Lombard Odier Asset Management (Switzerland) reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lombard Odier Asset Management (Switzerland) sold 317,901 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $2.65M.
  • Lombard Odier Asset Management (Switzerland) first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Lombard Odier Asset Management (Switzerland)'s BioCryst Pharmaceuticals position peaked at $2.65M in Q1 2023.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.